9BB12A25-E833-4055-8CEF-814EA5454F11
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.6938239159001314
- age_years
- 53
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.621
- E2F_TARGETS+0.564
- DNA_REPAIR+0.530
- MYC_TARGETS_V1+0.528
- MYC_TARGETS_V2+0.488
- INTERFERON_GAMMA_RESPONSE+0.482
- G2M_CHECKPOINT+0.476
- ANGIOGENESIS+0.455
- UNFOLDED_PROTEIN_RESPONSE+0.427
- TNFA_SIGNALING_VIA_NFKB+0.418
Top 10 suppressed
- KRAS_SIGNALING_DN-0.333
- SPERMATOGENESIS-0.278
- PANCREAS_BETA_CELLS-0.255
- MYOGENESIS-0.208
- APICAL_SURFACE-0.128
- BILE_ACID_METABOLISM-0.104
- HEDGEHOG_SIGNALING-0.062
- KRAS_SIGNALING_UP-0.033
- ESTROGEN_RESPONSE_EARLY-0.022
- UV_RESPONSE_DN-0.017
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.960 |
| 2 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.955 |
| 3 | AFE1F307-45A7-4155-8D51-FEBD6C92947C | — | — | 0.955 |
| 4 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.954 |
| 5 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.952 |
| 6 | C14BEAAE-A766-4ADE-A9B4-674D8717591F | — | — | 0.952 |
| 7 | A781FFD8-8A8D-4818-BD90-674295BE64D6 | — | — | 0.947 |
| 8 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.945 |
| 9 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.945 |
| 10 | D9385661-DBBA-4AF7-B7E6-857BF84CF7CD | — | — | 0.945 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.621 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.564 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.528 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.488 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.482 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.476 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.455 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.427 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.418 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.378 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.365 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.354 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.338 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.324 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.318 | Inavolisib | — uncovered |
| APOPTOSIS | 0.297 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.287 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.268 | Inavolisib | — uncovered |